Stem cells, cancer, and cancer stem cells, Nature, 2001. ,
Tumor necrosis factor-?? inhibits hTERT gene expression in human myeloid normal and leukemic cells, Blood, vol.106, issue.9, pp.3200-3205, 2005. ,
DOI : 10.1182/blood-2005-04-1386
Transcription factors in myeloid development: balancing differentiation with transformation, Nature Reviews Immunology, vol.14, issue.2, pp.105-122, 2007. ,
DOI : 10.1038/nri2024
Timeline: Leukaemia stem cells and the evolution of cancer-stem-cell research, Nature Reviews Cancer, vol.91, issue.4, pp.311-332, 2005. ,
DOI : 10.1038/nm1296-1329
SnapShot: hematopoiesis. Cell, Feb, vol.22132, issue.4, p.712, 2008. ,
DOI : 10.1016/j.cell.2008.02.013
URL : http://doi.org/10.1016/j.cell.2008.02.013
The hematopoietic stroma, Brazilian Journal of Medical and Biological Research, vol.32, issue.5, pp.601-610, 1999. ,
DOI : 10.1590/S0100-879X1999000500014
A cell initiating human acute myeloid leukaemia after transplantation into SCID mice, Nature, vol.367, issue.6464, pp.645-653, 1994. ,
DOI : 10.1038/367645a0
Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell, Nature Medicine, vol.6, issue.7, pp.730-737, 1997. ,
DOI : 10.1038/367645a0
Determination of P-glycoprotein, MDR-related protein 1, breast cancer resistance protein, and lung-resistance protein expression in leukemic stem cells of acute myeloid leukemia, Cytometry Part B: Clinical Cytometry, vol.128, issue.3, 2008. ,
DOI : 10.1002/cyto.b.20403
Acute myeloid leukaemia: a paradigm for the clonal evolution of cancer? Dis Model Mech, pp.941-51, 2014. ,
Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature The Cancer Genome Atlas Research Network. Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia, N Engl J Med, vol.499368, issue.745722, pp.214-222, 2013. ,
The roles of FLT3 in hematopoiesis and leukemia, Blood, vol.100, issue.5, pp.1532-1574, 2002. ,
DOI : 10.1182/blood-2002-02-0492
Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing, Nature, vol.115, issue.7382, pp.506-516, 2012. ,
DOI : 10.1038/nature10738
Isocitrate Dehydrogenase 1 and 2 Mutations in Cancer: Alterations at a Crossroads of Cellular Metabolism, JNCI Journal of the National Cancer Institute, vol.102, issue.13, pp.932-973, 2010. ,
DOI : 10.1093/jnci/djq187
Cancer-associated IDH mutations: biomarker and therapeutic opportunities, Oncogene, vol.324, issue.49, pp.6409-6426, 2009. ,
DOI : 10.1038/onc.2010.444
IDH mutations in glioma and acute myeloid leukemia, Trends in Molecular Medicine, vol.16, issue.9, 2010. ,
DOI : 10.1016/j.molmed.2010.07.002
The consensus coding sequences of human breast and colorectal cancers. Science An integrated genomic analysis of human glioblastoma multiforme. Science, pp.268-741807, 2006. ,
Recurring Mutations Found by Sequencing an Acute Myeloid Leukemia Genome, New England Journal of Medicine, vol.361, issue.11, pp.1058-66, 2009. ,
DOI : 10.1056/NEJMoa0903840
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3201812
Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations, The Journal of Experimental Medicine, vol.64, issue.2 ,
DOI : 10.1126/science.1170944
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2822606
Gene Mutations Identify Novel Molecular Subsets Within De Novo Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study, Journal of Clinical Oncology, vol.28, issue.14, pp.2348-55, 2010. ,
DOI : 10.1200/JCO.2009.27.3730
Identification of additional IDH mutations associated with oncometabolite R(???)-2-hydroxyglutarate production, Oncogene, vol.31, issue.19, pp.312491-312499, 2012. ,
DOI : 10.1016/j.bbrc.2010.10.038
IDH2 Mutations in Patients with D-2-Hydroxyglutaric Aciduria. Science, pp.336-336, 2010. ,
The Common Feature of Leukemia-Associated IDH1 and IDH2 Mutations Is a Neomorphic Enzyme Activity Converting ?-Ketoglutarate to 2-Hydroxyglutarate. Cancer Cell, pp.225-259, 2010. ,
IDH1 and IDH2 mutations in gliomas, N Engl J Med Feb, vol.19360, issue.8, pp.765-73, 2009. ,
Glioma-Derived Mutations in IDH1 Dominantly Inhibit IDH1 Catalytic Activity and Induce HIF-1. Science, pp.261-266, 2009. ,
Cancer-associated IDH1 mutations produce 2-hydroxyglutarate, Nature, vol.50, issue.7274, pp.739-783, 2009. ,
DOI : 10.1038/nature08617
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2818760
A Tale of Two Subunits: How the Neomorphic R132H IDH1 Mutation Enhances Production of ??HG, Biochemistry, vol.50, issue.21, pp.4804-4816, 2011. ,
DOI : 10.1021/bi200499m
Disruption of wild-type IDH1 suppresses D-2-hydroxyglutarate production in IDH1-mutated gliomas. Cancer Res, pp.496-501, 2013. ,
Metabolism of 2-amino-5-hydroxyadipic acid in the rat, Archives of Biochemistry and Biophysics, vol.119, issue.1, pp.347-52, 1967. ,
DOI : 10.1016/0003-9861(67)90463-8
D-2-hydroxyglutaric aciduria: Case report and biochemical studies, Journal of Inherited Metabolic Disease, vol.31, issue.1, pp.11-16, 1980. ,
DOI : 10.1007/BF02312516
Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of ?-ketoglutarate-dependent dioxygenases. Cancer Cell, pp.17-30, 2011. ,
Expanding chemical biology of 2-oxoglutarate oxygenases, Nature Chemical Biology, vol.4, issue.3, pp.152-158, 2008. ,
DOI : 10.1038/nature06145
IDH mutations in tumorigenesis and their potential role as novel therapeutic targets, Future Oncology, vol.9, issue.12, pp.1923-1958 ,
DOI : 10.2217/fon.13.143
Conversion of 5-Methylcytosine to 5-Hydroxymethylcytosine in Mammalian DNA by MLL Partner TET1, Science, vol.324, issue.5929, pp.930-935, 2009. ,
DOI : 10.1126/science.1170116
Emerging roles of TET proteins and 5-hydroxymethylcytosines in active DNA demethylation and beyond. Cell Cycle Georget Tex, pp.2662-2670, 2011. ,
Role of Tet proteins in 5mC to 5hmC conversion, ES-cell self-renewal and inner cell mass specification, Nature, vol.22, issue.7310, pp.1129-1162, 2010. ,
DOI : 10.1038/nature09303
5-Hydroxymethylcytosine is strongly depleted in human cancers but its levels do not correlate with IDH1 mutations. Cancer Res, pp.7360-7365, 2011. ,
Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell, pp.510-532, 2010. ,
URL : https://hal.archives-ouvertes.fr/hal-01201573
Methylation profiling identifies 2 groups of gliomas according to their tumorigenesis. Neuro-Oncol, pp.84-98, 2011. ,
DNA Methylation, Isocitrate Dehydrogenase Mutation, and Survival in Glioma, JNCI Journal of the National Cancer Institute, vol.103, issue.2, pp.143-53, 2011. ,
DOI : 10.1093/jnci/djq497
IDH1 Mutations Are Early Events in the Development of Astrocytomas and Oligodendrogliomas, The American Journal of Pathology, vol.174, issue.4, pp.1149-53, 2009. ,
DOI : 10.2353/ajpath.2009.080958
IDH mutation impairs histone demethylation and results in a block to cell differentiation, Nature, vol.249, issue.7390, pp.474-482, 2012. ,
DOI : 10.1038/nature10860
IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell, pp.479-83, 2010. ,
mutant acute myeloid leukemia: predicting patient responses, minimal residual disease and correlations with methylcytosine and hydroxymethylcytosine levels, Leukemia & Lymphoma, vol.54, issue.2, pp.408-418, 2013. ,
DOI : 10.1016/j.ccr.2010.11.015
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3688062
IDH1(R132H) mutation increases murine haematopoietic progenitors and alters epigenetics, Nature, vol.29, issue.7413, pp.656-665, 2012. ,
DOI : 10.1038/nature11323
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4005896
IDH mutation status impact on in vivo hypoxia biomarkers expression: new insights from a clinical, nuclear imaging and immunohistochemical study in 33 glioma patients, Journal of Neuro-Oncology, vol.13, issue.3, pp.591-600, 2011. ,
DOI : 10.1007/s11060-011-0625-2
(1)H NMR metabolomics identification of markers of hypoxiainduced metabolic shifts in a breast cancer model system, J Biomol NMR, vol.49, pp.3-4185, 2011. ,
Hypoxia-Inducible Factors and the Response to Hypoxic Stress, Molecular Cell, vol.40, issue.2 ,
DOI : 10.1016/j.molcel.2010.09.022
D-2-hydroxyglutarate produced by mutant IDH1 perturbs collagen maturation and basement membrane function, Genes & Development, vol.26, issue.18, pp.2038-2087, 2012. ,
DOI : 10.1101/gad.198200.112
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3444730
The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases, EMBO reports, vol.1815, issue.5, pp.463-472, 2011. ,
DOI : 10.1126/science.1170944
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3090014
Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation, Nature, vol.37, issue.7390, pp.484-492, 2012. ,
DOI : 10.1038/nature10898
(R)-2-Hydroxyglutarate Is Sufficient to Promote Leukemogenesis and Its Effects Are Reversible, Science, vol.339, issue.6127, pp.1621-1626, 2013. ,
DOI : 10.1126/science.1231677
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3836459
R132H-mutation of isocitrate dehydrogenase-1 is not sufficient for HIF-1?? upregulation in adult glioma, Acta Neuropathologica, vol.324, issue.2 ,
DOI : 10.1007/s00401-010-0790-y
SDH mutations in cancer, Biochimica et Biophysica Acta (BBA) - Bioenergetics, vol.1807, issue.11, 2011. ,
DOI : 10.1016/j.bbabio.2011.07.003
URL : http://doi.org/10.1016/j.bbabio.2011.07.003
Endostatin: An Endogenous Inhibitor of Angiogenesis and Tumor Growth, Cell, vol.88, issue.2, pp.277-85, 1997. ,
DOI : 10.1016/S0092-8674(00)81848-6
Hallmarks of cancer: the next generation. Cell, pp.646-74, 2011. ,
Evidence of increased microvessel density and activation of the hypoxia pathway in tumours from the hereditary leiomyomatosis and renal cell cancer syndrome Succinate inhibition of alpha-ketoglutarate-dependent enzymes in a yeast model of paraganglioma, J Pathol. Hum Mol Genet, vol.20516, issue.124, pp.41-50, 2005. ,
Profiling the effects of isocitrate dehydrogenase 1 and 2 mutations on the cellular metabolome, Proceedings of the National Academy of Sciences, vol.108, issue.8, pp.3270-3275, 2011. ,
DOI : 10.1073/pnas.1019393108
Mitochondrial energy metabolism is markedly impaired by d-2-hydroxyglutaric acid in rat tissues, Molecular Genetics and Metabolism, vol.86, issue.1-2, pp.188-99, 2005. ,
DOI : 10.1016/j.ymgme.2005.05.002
-2-hydroxyglutaric aciduria, European Journal of Neuroscience, vol.16, issue.Suppl. 1 ,
DOI : 10.1002/1531-8249(199901)45:1<111::aid-art17>3.0.co;2-n
ATP-citrate lyase links cellular metabolism to histone acetylation. Science, pp.1076-80, 2009. ,
DOI : 10.1126/science.1164097
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2746744
Silencing of selected glutamate receptor subunits modulates cancer growth, Anticancer Res, vol.31, issue.10, pp.3181-92, 2011. ,
AMPA receptors promote perivascular glioma invasion via beta1 integrindependent adhesion to the extracellular matrix. Neuro-Oncol, pp.260-73, 2009. ,
Autocrine glutamate signaling promotes glioma cell invasion. Cancer Res, pp.9463-71, 2007. ,
DOI : 10.1158/0008-5472.can-07-2034
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2045073
Inhibition of glutaminase preferentially slows growth of glioma cells with mutant IDH1. Cancer Res, pp.8981-8988, 2010. ,
Diabetes Mellitus and Increased Risk of Cancer: Focus on Metformin and the Insulin Analogs, Pharmacotherapy, vol.31, issue.11, pp.1159-78, 2010. ,
DOI : 10.2337/db09-1371
A Pyruvate Cycling Pathway Involving Cytosolic NADP-dependent Isocitrate Dehydrogenase Regulates Glucose-stimulated Insulin Secretion, Journal of Biological Chemistry, vol.281, issue.41, pp.30593-602, 2006. ,
DOI : 10.1074/jbc.M511908200
D-2-hydroxyglutaric acid induces oxidative stress in cerebral cortex of young rats, European Journal of Neuroscience, vol.77, issue.Suppl. 1, pp.2017-2039, 2003. ,
DOI : 10.1046/j.1460-9568.2003.02639.x
IDH mutations in acute myeloid leukemia, Human Pathology, vol.43, issue.10, pp.1541-51 ,
DOI : 10.1016/j.humpath.2012.05.003
Mutations in Gliomas, New England Journal of Medicine, vol.360, issue.8, pp.765-73, 2009. ,
DOI : 10.1056/NEJMoa0808710
Differential prognostic effect of IDH1 versus IDH2 mutations in myelodysplastic syndromes: a Mayo Clinic Study of 277 patients, Leukemia, vol.26, issue.1, pp.101-106, 2012. ,
DOI : 10.1002/ajh.21984
IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis, Leukemia, vol.114, issue.7, pp.1302-1311, 2010. ,
DOI : 10.1182/blood-2008-12-194548
Mutation Analysis of Isocitrate Dehydrogenase in Acute Lymphoblastic Leukemia, Genetic Testing and Molecular Biomarkers, vol.16, issue.8, pp.991-996, 2012. ,
DOI : 10.1089/gtmb.2011.0323
Internal Tandem Duplication, Journal of Clinical Oncology, vol.28, issue.22, pp.3636-3679, 2010. ,
DOI : 10.1200/JCO.2010.28.3762
Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: prevalence and prognostic value, Blood, vol.116, issue.12, pp.2122-2128, 2010. ,
DOI : 10.1182/blood-2009-11-250878
Mutation, American Journal of Clinical Pathology, vol.135, issue.1, pp.35-45, 2011. ,
DOI : 10.1309/AJCPD7NR2RMNQDVF
URL : https://hal.archives-ouvertes.fr/hal-00552549
Prevalence and prognostic value of IDH1 and IDH2 mutations in childhood AML: a study of the AML???BFM and DCOG study groups, Leukemia, vol.114, issue.11, pp.1704-1714, 2011. ,
DOI : 10.1038/leu.2010.251
The prognostic significance of IDH1 mutations in younger adult patients with acute myeloid leukemia is dependent on FLT3/ITD status, Blood, vol.116, issue.15, 2010. ,
DOI : 10.1182/blood-2010-02-270926
IDH mutations in acute myeloid leukemia, Human Pathology, vol.43, issue.10, pp.1541-51 ,
DOI : 10.1016/j.humpath.2012.05.003
étude à parxr des registres des cancers du réseau Francim. Saint-Maurice: Institut de veille sanitaire; 2013 Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet, Blood, vol.115, issue.3, pp.453-74, 1980. ,
The 2016 revision to the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia ,
Acute myeloid leukemia Independent prognostic variables in acute myeloid leukaemia, N Engl J Med Blood Rev, vol.34125, issue.141, pp.1051-62, 1999. ,
The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML. Blood, Feb, vol.17117, issue.7, pp.2137-2182, 2011. ,
Clinical characterization of acute myeloid leukemia with myelodysplasia-related changes as defined by the 2008 WHO classification system, Blood, vol.113, issue.9, pp.1906-1914, 2009. ,
DOI : 10.1182/blood-2008-10-182782
Multilineage dysplasia (MLD) in acute myeloid leukemia (AML) correlates with MDS-related cytogenetic abnormalities and a prior history of MDS or MDS/MPN but has no independent prognostic relevance: a comparison of 408 cases classified as "AML not otherwise specified" (AML-NOS) or "AML with myelodysplasia-related changes" (AML-MRC), Blood, vol.116, issue.15, pp.2742-51, 2010. ,
DOI : 10.1182/blood-2010-04-279794
Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials, Blood, vol.116, issue.3, pp.354-65, 2010. ,
DOI : 10.1182/blood-2009-11-254441
Monosomal karyotype in adult acute myeloid leukemia: prognostic impact and outcome after different treatment strategies, Blood, vol.119, issue.2, pp.551-559, 2012. ,
DOI : 10.1182/blood-2011-07-367508
URL : http://mediatum.ub.tum.de/doc/1181634/document.pdf
Double CEBPA mutations, but not single CEBPA mutations, define a subgroup of acute myeloid leukemia with a distinctive gene expression profile that is uniquely associated with a favorable outcome, Blood, vol.113, issue.13, pp.3088-91, 2009. ,
DOI : 10.1182/blood-2008-09-179895
A novel hierarchical prognostic model of AML solely based on molecular mutations, Blood, vol.120, issue.15, pp.2963-72, 2012. ,
DOI : 10.1182/blood-2012-03-419622
Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia, New England Journal of Medicine, vol.366, issue.12, pp.1079-89, 2012. ,
DOI : 10.1056/NEJMoa1112304
A Modified Integrated Genetic Model for Risk Prediction in Younger Patients with Acute Myeloid Leukemia, PLOS ONE, 2016. ,
DOI : 10.1371/journal.pone.0153016.s002
FLT3 tyrosine kinase domain mutations are biologically distinct from and have a significantly more favorable prognosis than FLT3 internal tandem duplications in patients with acute myeloid leukemia. Blood, pp.1262-70, 2007. ,
Prognostic Impact of Isocitrate Dehydrogenase Enzyme Isoforms 1 and 2 Mutations in Acute Myeloid Leukemia: A Study by the Acute Leukemia French Association Group, Journal of Clinical Oncology, vol.28, issue.23, pp.3717-3740, 2010. ,
DOI : 10.1200/JCO.2010.28.2285
The prognostic significance of IDH2 mutations in AML depends on the location of the mutation, Blood, vol.118, issue.2, pp.409-421, 2011. ,
DOI : 10.1182/blood-2010-12-322479
Prognostic impact of IDH2 mutations in cytogenetically normal acute myeloid leukemia, Blood, vol.116, issue.4, pp.614-620, 2010. ,
DOI : 10.1182/blood-2010-03-272146
Single Nucleotide Polymorphism in Cytogenetically Normal Acute Myeloid Leukemia: SNP rs11554137 Is an Adverse Prognostic Factor, Journal of Clinical Oncology, vol.28, issue.14, pp.2356-64, 2010. ,
DOI : 10.1200/JCO.2009.27.6899
Distinct clinical and biologic characteristics in adult acute myeloid leukemia bearing the isocitrate dehydrogenase 1 mutation, Blood, vol.115, issue.14, 2010. ,
DOI : 10.1182/blood-2009-11-253070
The prognostic impact and stability of Isocitrate dehydrogenase 2 mutation in adult patients with acute myeloid leukemia, Leukemia, vol.268, issue.2, 2011. ,
DOI : 10.1038/ncponc0097
High incidence of IDH mutations in acute myeloid leukaemia with cuplike nuclei, British Journal of Haematology, vol.360, issue.1, pp.125-133, 2011. ,
DOI : 10.1111/j.1365-2141.2011.08646.x
IDH1 and IDH2 mutations in pediatric acute leukemia, Leukemia, vol.92, issue.10, pp.1570-1577, 2011. ,
DOI : 10.1182/blood.V99.12.4326
Low prevalence of IDH1 gene mutation in childhood AML in Italy, Leukemia, vol.25, issue.1, pp.173-177, 2011. ,
DOI : 10.1182/blood-2009-11-253070
Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients, Blood, vol.113, issue.1, 2009. ,
DOI : 10.1182/blood-2008-05-157065
Early clearance of peripheral blasts measured by flow cytometry during the first week of AML induction therapy as a new independent prognostic factor: a GOELAMS study, Leukemia, vol.22, issue.2, pp.350-357, 2009. ,
DOI : 10.1038/leu.2008.296
Early peripheral blood blast clearance during induction chemotherapy for acute myeloid leukemia predicts superior relapse-free survival, Blood, vol.110, issue.13, pp.4172-4176, 2007. ,
DOI : 10.1182/blood-2007-07-104091
An update of current treatments for adult acute myeloid leukemia, Blood, vol.127, issue.1, p.2016 ,
DOI : 10.1182/blood-2015-08-604520
Anthracycline Dose Intensification in Acute Myeloid Leukemia, New England Journal of Medicine, vol.361, issue.13, pp.1249-59, 2009. ,
DOI : 10.1056/NEJMoa0904544
High Dose Daunorubicin Improves Survival in AML up to Age 60, Across All Cytogenetic Risk Groups Including Patients with Unfavorable Cytogenetic Risk, and FLT3-ITD Mutant AML: Updated Analyses from Eastern Cooperative Oncology Trial E1900, Blood, vol.124, issue.21, pp.373-373, 2014. ,
High-Dose Daunorubicin in Older Patients with Acute Myeloid Leukemia, New England Journal of Medicine, vol.361, issue.13, pp.1235-1283, 2009. ,
DOI : 10.1056/NEJMoa0901409
A randomized trial comparing standard versus high-dose daunorubicin induction in patients with acute myeloid leukemia, Blood, vol.118, issue.14, pp.3832-3873, 2011. ,
DOI : 10.1182/blood-2011-06-361410
A randomized comparison of daunorubicin 90 mg/m2 vs 60 mg/m2 in AML induction: results from the UK NCRI AML17 trial in 1206 patients, Blood, vol.125, issue.25, pp.3878-85, 2015. ,
DOI : 10.1182/blood-2015-01-623447
Randomized Study of Intensified Anthracycline Doses for Induction and Recombinant Interleukin-2 for Maintenance in Patients With Acute Myeloid Leukemia Age 50 to 70 Years: Results of the ALFA-9801 Study, Journal of Clinical Oncology, vol.28, issue.5, pp.808-822, 2010. ,
DOI : 10.1200/JCO.2009.23.2652
URL : https://hal.archives-ouvertes.fr/hal-00453228
Randomized study of induction therapy comparing standard-dose idarubicin with high-dose daunorubicin in adult patients with previously untreated acute myeloid leukemia: the JALSG AML201 Study, Blood, vol.117, issue.8, pp.2358-65, 2011. ,
DOI : 10.1182/blood-2010-03-273243
A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study, Blood, vol.88, issue.8, pp.2841-51, 1996. ,
A randomized study of high-dose cytarabine in induction in acute myeloid leukemia, Blood, vol.87, issue.5, pp.1710-1717, 1996. ,
Cytarabine Dose for Acute Myeloid Leukemia, New England Journal of Medicine, vol.364, issue.11, pp.1027-1063, 2011. ,
DOI : 10.1056/NEJMoa1010222
High-Dose Cytarabine in Induction Treatment Improves the Outcome of Adult Patients Younger Than Age 46 Years With Acute Myeloid Leukemia: Results of the EORTC-GIMEMA AML-12 Trial, Journal of Clinical Oncology, vol.32, issue.3, pp.219-247, 2014. ,
DOI : 10.1200/JCO.2013.51.8571
A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia, Blood, vol.121, issue.24, pp.4854-60, 2013. ,
DOI : 10.1182/blood-2013-01-466706
Identification of Patients With Acute Myeloblastic Leukemia Who Benefit From the Addition of Gemtuzumab Ozogamicin: Results of the MRC AML15 Trial, Journal of Clinical Oncology, vol.29, issue.4, pp.369-77, 2011. ,
DOI : 10.1200/JCO.2010.31.4310
Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study, The Lancet, vol.379, issue.9825, pp.1508-1524, 2012. ,
DOI : 10.1016/S0140-6736(12)60485-1
URL : https://hal.archives-ouvertes.fr/hal-01056520
Addition of Gemtuzumab Ozogamicin to Induction Chemotherapy Improves Survival in Older Patients With Acute Myeloid Leukemia, Journal of Clinical Oncology, vol.30, issue.32, pp.3924-3955, 2012. ,
DOI : 10.1200/JCO.2012.42.2964
Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials, The Lancet Oncology, vol.15, issue.9, pp.986-96, 2014. ,
DOI : 10.1016/S1470-2045(14)70281-5
Gemtuzumab ozogamicin as postremission treatment in AML at 60 years of age or more: results of a multicenter phase 3 study, Blood, vol.115, issue.13, pp.2586-2591, 2010. ,
DOI : 10.1182/blood-2009-10-246470
Cladribine, But Not Fludarabine, Added to Daunorubicin and Cytarabine During Induction Prolongs Survival of Patients With Acute Myeloid Leukemia: A Multicenter, Randomized Phase III Study, Journal of Clinical Oncology, vol.30, issue.20, pp.2441-2449, 2012. ,
DOI : 10.1200/JCO.2011.37.1286
Clofarabine and cytarabine combination as induction therapy for acute myeloid leukemia (AML) in patients 50 years of age or older, Blood, vol.108, issue.1, pp.45-51, 2006. ,
DOI : 10.1182/blood-2005-08-3294
Phase II Study of Clofarabine Monotherapy in Previously Untreated Older Adults With Acute Myeloid Leukemia and Unfavorable Prognostic Factors, Journal of Clinical Oncology, vol.28, issue.4, pp.549-55, 2010. ,
DOI : 10.1200/JCO.2009.23.3130
Clofarabine in combination with a standard remission induction regimen (cytosine arabinoside and idarubicin) in patients with previously untreated intermediate and bad-risk acute myelogenous leukemia (AML) or high-risk myelodysplastic syndrome (HR-MDS): phase I results of an ongoing phase I/II study of the leukemia groups of EORTC and GIMEMA (EORTC GIMEMA 06061/AML-14A trial), Annals of Hematology, vol.21, issue.5, 2014. ,
DOI : 10.1007/s00277-014-2056-6
Optimization of Chemotherapy for Younger Patients With Acute Myeloid Leukemia: Results of the Medical Research Council AML15 Trial, Journal of Clinical Oncology, vol.31, issue.27, pp.3360-3368, 2013. ,
DOI : 10.1200/JCO.2012.47.4874
Sorafenib in Combination With Intensive Chemotherapy in Elderly Patients With Acute Myeloid Leukemia: Results From a Randomized, Placebo-Controlled Trial, Journal of Clinical Oncology, vol.31, issue.25, pp.313110-313118, 2013. ,
DOI : 10.1200/JCO.2012.46.4990
Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom?, Blood, vol.109, issue.9, 2007. ,
DOI : 10.1182/blood-2006-06-025627
Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia in First Complete Remission, JAMA, vol.301, issue.22, pp.1909-1927, 2008. ,
DOI : 10.1001/jama.2009.813
A comparative assessment of the curative potential of reduced intensity allografts in acute myeloid leukaemia, Leukemia, vol.92, issue.7, pp.1478-84 ,
DOI : 10.1182/blood-2004-02-0545
Comparative therapeutic value of post-remission approaches in patients with acute myeloid leukemia aged 40???60 years, Leukemia, vol.1, issue.5, pp.1041-50, 2015. ,
DOI : 10.1002/bimj.4710280508
Conditioning intensity in middleaged patients with AML in first CR: no advantage for myeloablative regimens irrespective of the risk group?an observational analysis by the Acute Leukemia Working Party of the EBMT, Bone Marrow Transplant, 2015. ,
Dasatinib in high-risk core binding factor acute myeloid leukemia in first complete remission: a French Acute Myeloid Leukemia Intergroup trial, Haematologica, vol.100, issue.6, pp.780-785, 2015. ,
DOI : 10.3324/haematol.2014.114884
Dasatinib (DAS) in combination with chemotherapy and as maintenance in core-binding factor (CBF) acute myeloid leukemia (AML): a phase Ib/IIa study of the German- Austrian AML Study Group (AMLSG) [abstract], Haematologica, vol.100, issue.s1, 2015. ,
Adding KIT inhibitor dasatinib (DAS) to chemotherapy overcomes the negative impact of KIT mutation/over-expression in core binding factor (CBF) acute myeloid leukemia (AML): results from CALGB 10801 (Alliance) [abstract] Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse, Blood Blood, vol.124, issue.21, 2011. ,
A randomised comparison of the sequential addition of the FLT3 inhibitor lestaurtinib (CEP701) to standard first line chemotherapy for FLT3-mutated acute myeloid leukemia: The UK experience [abstract] Secondary mutations as mediators of resistance to targeted therapy in leukemia, Blood Blood, vol.124125, issue.2121, pp.3236-3281, 2014. ,
The impact on outcome of the addition of all-trans retinoic acid to intensive chemotherapy in younger patients with nonacute promyelocytic acute myeloid leukemia: overall results and results in genotypic subgroups defined by mutations in NPM1, FLT3, and CEBPA, Blood, vol.115, issue.5, pp.948-56, 2010. ,
DOI : 10.1182/blood-2009-08-236588
Gene mutations and response to treatment with all-trans retinoic acid in elderly patients with acute myeloid leukemia. Results from the AMLSG Trial AML HD98B, Haematologica, vol.94, issue.1, pp.54-60, 2009. ,
DOI : 10.3324/haematol.13378
Retinoic acid and arsenic trioxide trigger degradation of mutated NPM1, resulting in apoptosis of AML cells. Blood, pp.3447-54, 2015. ,
Arsenic trioxide and all-trans retinoic acid target NPM1 mutant oncoprotein levels and induce apoptosis in NPM1-mutated AML cells, Blood, vol.125, issue.22, pp.3455-65, 2015. ,
DOI : 10.1182/blood-2014-11-611459
Targeted Inhibition of Mutant IDH2 in Leukemia Cells Induces Cellular Differentiation, Science, vol.340, issue.6132, pp.622-628, 2013. ,
DOI : 10.1126/science.1234769
An Inhibitor of Mutant IDH1 Delays Growth and Promotes Differentiation of Glioma Cells, Science, vol.340, issue.6132, pp.626-656, 2013. ,
DOI : 10.1126/science.1236062
IDH2 mutation-induced histone and DNA hypermethylation is progressively reversed by small-molecule inhibition. Blood, pp.296-303, 2015. ,
DOI : 10.1182/blood-2013-10-533604
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4295919
AG-221, an oral, selective, fi rst-in-class,potent inhibitor of the IDH2 mutant enzyme, induced durable responses in a phaseI study of IDH2 mutation-positive advanced hematologic malignancies, EuropeanHematology Association Learning Center 13, 2015. ,
Molecular profiling and relationship with clinical response in patients with IDH1 mutation-positive hematologic malignancies receiving AG-120, a first-in-class potent inhibitor of mutant IDH1, in addition to data from the completed dose escalation portion of the phase 1 study, Blood, pp.126-1306, 2015. ,
Evidence for Clinical Differentiation and Differentiation Syndrome in Patients With ,
AG-120 Clin Lymphoma Myeloma Leuk Presence of isocitrate dehydrogenase mutations may predict clinical response to hypomethylating agents in patients with acute myeloid leukemia, Acute Myeloid Leukemia and IDH1 Mutations Treated With the Targeted Mutant IDH1 Inhibitor, pp.77-86, 2015. ,
DNMT3A mutations and response to the hypomethylating agent decitabine in acute myeloid leukemia, Leukemia, vol.468, issue.5, 2012. ,
DOI : 10.1038/leu.2011.342
mutations with outcome in older patients with acute myeloid leukemia treated with hypomethylating agents, Leukemia & Lymphoma, vol.55, issue.8, pp.1925-1934, 2014. ,
DOI : 10.1182/blood-2011-07-367961
A vaccine targeting mutant IDH1 induces antitumour immunity, Nature, vol.124, issue.7514, pp.324-331, 2014. ,
DOI : 10.1038/nature13387
Effective immuno-targeting of the IDH1 mutation R132H in a murine model of intracranial glioma, Acta Neuropathologica Communications, vol.210, issue.1, p.4, 2015. ,
DOI : 10.1186/s40478-014-0180-0
IDH mutations in cancer and progress toward development of targeted therapeutics, Annals of Oncology, vol.27, issue.4, pp.599-608 ,
DOI : 10.1093/annonc/mdw013
Cladribine, cytarabine, filgrastim, and mitoxantrone (CLAG-M) compared to standard induction in acute myeloid leukemia from myelodysplastic syndrome after azanucleoside failure, Leukemia Research, vol.38, issue.4, pp.443-449 ,
DOI : 10.1016/j.leukres.2013.12.010
Mutations in Older Patients With Cytogenetically Normal De Novo Acute Myeloid Leukemia and Associated Gene- and MicroRNA-Expression Signatures: A Cancer and Leukemia Group B Study, Journal of Clinical Oncology, vol.28, issue.4, pp.596-604, 2010. ,
DOI : 10.1200/JCO.2009.25.1496
Superior Long-Term Outcome With Idarubicin Compared With High-Dose Daunorubicin in Patients With Acute Myeloid Leukemia Age 50 Years and Older, Journal of Clinical Oncology, vol.31, issue.3, pp.321-328, 2013. ,
DOI : 10.1200/JCO.2011.40.3642
A comparison of lowdose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and highrisk myelodysplastic syndrome in patients not considered fit for intensive treatment. Cancer, pp.1114-1138, 2007. ,
Multicenter, Randomized, Open-Label, Phase III Trial of Decitabine Versus Patient Choice, With Physician Advice, of Either Supportive Care or Low-Dose Cytarabine for the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia, Journal of Clinical Oncology, vol.30, issue.21, pp.2670-2677, 2012. ,
DOI : 10.1200/JCO.2011.38.9429
Randomized, phase 2 trial of low-dose cytarabine with or without volasertib in AML patients not suitable for induction therapy, Blood, vol.124, issue.9, pp.1426-1459, 2014. ,
DOI : 10.1182/blood-2014-03-560557
Phase I/II study of vosaroxin and decitabine in newly diagnosed older patients (pts) with acute myeloid leukemia (AML) and high risk myelodysplastic syndrome (MDS) [abstract] Curability of Patients With Acute Myeloid Leukemia Who Did Not Undergo Transplantation in First Remission, Blood J Clin Oncol, vol.124, issue.2110, pp.311293-301, 2013. ,
The effect of chemotherapy on acute leukemia in the human, Journal of Chronic Diseases, vol.14, issue.6, pp.593-608, 1961. ,
DOI : 10.1016/0021-9681(61)90118-7
Detection of minimal residual disease in acute leukemia: methodologic advances and clinical significance, Blood. Mar, vol.1585, issue.6, pp.1416-1450, 1995. ,
New score predicting for prognosis in PML-RARA+, AML1-ETO+, or CBFBMYH11+ acute myeloid leukemia based on quantification of fusion transcripts, Blood, vol.102, issue.8, pp.2746-55, 2003. ,
DOI : 10.1182/blood-2003-03-0880
Minimal residual core binding factor AMLs by real time quantitative PCR???Initial response to chemotherapy predicts event free survival and close monitoring of peripheral blood unravels the kinetics of relapse, Leukemia Research, vol.30, issue.4, pp.389-95, 2006. ,
DOI : 10.1016/j.leukres.2005.08.030
Relapse prediction in acute myeloid leukaemia patients in complete remission using WT1 as a molecular marker: development of a mathematical model to predict time from molecular to clinical relapse and define optimal sampling intervals, British Journal of Haematology, vol.47, issue.6, pp.782-91, 2008. ,
DOI : 10.1038/sj.leu.2403809
Early prediction of treatment outcome in acute myeloid leukemia by measurement of WT1 transcript levels in peripheral blood samples collected after chemotherapy, Haematologica, vol.93, issue.6, pp.921-925, 2008. ,
DOI : 10.3324/haematol.12165
Assay to Enhance Risk Stratification in Acute Myeloid Leukemia: A European LeukemiaNet Study, Journal of Clinical Oncology, vol.27, issue.31, pp.5195-201, 2009. ,
DOI : 10.1200/JCO.2009.22.4865
Prognostic Relevance of Treatment Response Measured by Flow Cytometric Residual Disease Detection in Older Patients With Acute Myeloid Leukemia, Journal of Clinical Oncology, vol.31, issue.32, pp.314123-314154, 2013. ,
DOI : 10.1200/JCO.2013.49.1753
High Prognostic Impact of Flow Cytometric Minimal Residual Disease Detection in Acute Myeloid Leukemia: Data From the HOVON/SAKK AML 42A Study, Journal of Clinical Oncology, vol.31, issue.31, pp.313889-97, 2013. ,
DOI : 10.1200/JCO.2012.45.9628
-Mutated Acute Myeloid Leukemia: A Study From the German-Austrian Acute Myeloid Leukemia Study Group, Journal of Clinical Oncology, vol.29, issue.19, pp.2709-2725, 2011. ,
DOI : 10.1200/JCO.2011.35.0371
Strikingly different molecular relapse kinetics in NPM1c, PML-RARA, RUNX1-RUNX1T1, and CBFB-MYH11 acute myeloid leukemias, Blood, vol.115, issue.2, pp.198-205, 2010. ,
DOI : 10.1182/blood-2009-04-212530
Minimal residual disease monitoring by quantitative RT-PCR in core binding factor AML allows risk stratification and predicts relapse: results of the United Kingdom MRC AML-15 trial, Blood, vol.120, issue.14, pp.2826-2861, 2012. ,
DOI : 10.1182/blood-2012-06-435669
Relapse kinetics in acute myeloid leukaemias with MLL translocations or partial tandem duplications within the MLL gene, Br J Haematol. 2014, vol.165, issue.5, pp.618-646 ,
fusion transcript in acute myeloid leukaemia, European Journal of Haematology, vol.158, issue.5, pp.394-402, 2013. ,
DOI : 10.1111/ejh.12156
-positive acute myeloid leukemia patients, European Journal of Haematology, vol.36, issue.5, pp.436-477, 2015. ,
DOI : 10.1111/ejh.12511
URL : https://hal.archives-ouvertes.fr/hal-00509049
Prognostic impact of RT-PCR-based quantification of WT1 gene expression during MRD monitoring of acute myeloid leukemia, Leukemia, vol.25, issue.8, pp.1416-1439, 2005. ,
DOI : 10.1038/sj.leu.2403809
gene expression before haematopoietic stem cell transplant in children with acute myeloid leukaemia predicts poor event-free survival, British Journal of Haematology, vol.97, issue.6, pp.669-74, 2009. ,
DOI : 10.1111/j.1365-2141.2009.07770.x
Impact of Pretransplantation Minimal Residual Disease, As Detected by Multiparametric Flow Cytometry, on Outcome of Myeloablative Hematopoietic Cell Transplantation for Acute Myeloid Leukemia, Journal of Clinical Oncology, vol.29, issue.9, pp.1190-1197, 2011. ,
DOI : 10.1200/JCO.2010.31.8121
Optimal time-points for minimal residual disease monitoring change on the basis of the method used in patients with acute myeloid leukemia who underwent allogeneic stem cell transplantation: A comparison between multiparameter flow cytometry and Wilms??? tumor 1 expression, Leukemia Research, vol.39, issue.2, pp.138-181, 2015. ,
DOI : 10.1016/j.leukres.2014.11.011
Standardization and quality control studies of ???real-time??? quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia ??? A Europe Against Cancer Program, Leukemia, vol.17, issue.12, 2003. ,
DOI : 10.1038/sj.leu.2403135
A real-time quantitative RT-PCR assay for monitoring DEK-CAN fusion transcripts arising from translocation t(6;9) in acute myeloid leukemia, Leukemia Research, vol.28, issue.11, pp.1213-1218, 2004. ,
DOI : 10.1016/j.leukres.2004.03.011
Quantification of DEK-CAN fusion transcript by real-time reverse transcription polymerase reaction in patients with t(6;9) acute myeloid leukemia, Haematologica, 2004. ,
Prospective long-term minimal residual disease monitoring using RQ-PCR in RUNX1-RUNX1T1-positive acute myeloid leukemia: results of the French CBF-2006 trial, Haematologica, vol.101, issue.3, pp.328-363, 2016. ,
DOI : 10.3324/haematol.2015.131946
Defining minimal residual disease in acute myeloid leukemia: which platforms are ready for " prime time " ? Blood, pp.3345-55, 2014. ,
DOI : 10.1182/asheducation-2014.1.222
Quantitative assessment of minimal residual disease in acute myeloid leukemia carrying nucleophosmin (NPM1) gene mutations, Leukemia, vol.106, issue.6, pp.1103-1111, 2006. ,
DOI : 10.1038/sj.leu.2404149
Prognostic and therapeutic implications of minimal residual disease detection in acute myeloid leukemia. Blood, pp.332-373, 2012. ,
Beyond morphology, Current Opinion in Hematology, vol.19, issue.2, pp.82-90 ,
DOI : 10.1097/MOH.0b013e3283501325
The role of multiparameter flow cytometry for disease monitoring in AML, Best Practice & Research Clinical Haematology, vol.23, issue.3, pp.379-90, 2010. ,
DOI : 10.1016/j.beha.2010.06.007
Expression of the hMICL in acute myeloid leukemiaa highly reliable disease marker at diagnosis and during follow-up, Cytometry B Clin Cytom. 2012, vol.82, issue.1, pp.3-8 ,
Aberrant marker expression patterns on the CD34+CD38??? stem cell compartment in acute myeloid leukemia allows to distinguish the malignant from the normal stem cell compartment both at diagnosis and in remission, Leukemia, vol.18, issue.8, 2007. ,
DOI : 10.1038/sj.leu.2404754
hMICL and CD123 in combination with a CD45/CD34/CD117 backbone - a universal marker combination for the detection of minimal residual disease in acute myeloid leukaemia, British Journal of Haematology, vol.62, issue.2, pp.212-234, 2014. ,
DOI : 10.1111/bjh.12614
Wilms' tumor 1 mutation accumulated during therapy in acute myeloid leukemia: biological and clinical implications, Leukemia, vol.91, issue.11, pp.2051-2055, 2006. ,
DOI : 10.1182/blood-2005-04-1656
High-frequency type I/II mutational shifts between diagnosis and relapse are associated with outcome in pediatric AML: implications for personalized medicine, Blood, vol.116, issue.15, pp.2752-2760, 2010. ,
DOI : 10.1182/blood-2010-03-276519
Next-generation sequencing of FLT3 internal tandem duplications for minimal residual disease monitoring in acute myeloid leukemia, Oncotarget, vol.6, issue.26, pp.22812-22833, 2015. ,
DOI : 10.18632/oncotarget.4333
Sensitive measurement of quantity dynamics of FLT3 internal tandem duplication at early time points provides prognostic information, Annals of Oncology, vol.22, issue.3, pp.696-704, 2011. ,
DOI : 10.1093/annonc/mdq402
Minimal residual disease monitoring based on FLT3 internal tandem duplication in adult acute myeloid leukemia, Leukemia Research, vol.36, issue.3, 2012. ,
DOI : 10.1016/j.leukres.2011.11.002
MRD parameters using immunophenotypic detection methods are highly reliable in predicting survival in acute myeloid leukaemia, Leukemia, vol.18, issue.8, pp.1380-90, 2004. ,
DOI : 10.1038/sj.leu.2403405
Stability of leukemiaassociated aberrant immunophenotypes in patients with acute myeloid leukemia between diagnosis and relapse: comparison with cytomorphologic, cytogenetic, and molecular genetic findings, Cytometry B Clin Cytom, vol.62, issue.1, pp.25-38, 2004. ,
Age-Related Clonal Hematopoiesis Associated with Adverse Outcomes, New England Journal of Medicine, vol.371, issue.26, pp.2488-98, 2014. ,
DOI : 10.1056/NEJMoa1408617
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4306669
Clonal Hematopoiesis and Blood-Cancer Risk Inferred from Blood DNA Sequence, New England Journal of Medicine, vol.371, issue.26, pp.2477-87, 2014. ,
DOI : 10.1056/NEJMoa1409405
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4290021
mutations at long-term remission in adult patients with AML, British Journal of Haematology, vol.43, issue.4, pp.478-86, 2014. ,
DOI : 10.1111/bjh.13062
IDH1/2 but not DNMT3A mutations are suitable targets for minimal residual disease monitoring in acute myeloid leukemia patients: a study by the Acute Leukemia French Association, Oncotarget, vol.6, issue.39, pp.42345-53, 2015. ,
Monitoring minimal residual disease in acute myeloid leukaemia: a review of the current evolving strategies, Therapeutic Advances in Hematology, vol.121, issue.1, pp.3-16 ,
DOI : 10.1111/bjh.13062
Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial, The Lancet Oncology, vol.11, issue.6, 2010. ,
DOI : 10.1016/S1470-2045(10)70090-5
MRD-directed risk stratification treatment may improve outcomes of t(8;21) AML in the first complete remission: results from the AML05 multicenter trial, Blood, vol.121, issue.20, pp.4056-62, 2013. ,
DOI : 10.1182/blood-2012-11-468348
expression, British Journal of Haematology, vol.83, issue.4, 2013. ,
DOI : 10.1111/bjh.12181
Minimal residual disease-directed preemptive treatment with azacitidine in patients with NPM1-mutant acute myeloid leukemia and molecular relapse, Haematologica, vol.96, issue.10, pp.1568-70, 2011. ,
DOI : 10.3324/haematol.2011.044388
URL : http://doi.org/10.3324/haematol.2011.044388
Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial, Leukemia, vol.116, issue.3, pp.381-390, 2012. ,
DOI : 10.1038/leu.2011.234
Persistence of mutant isocitrate dehydrogenase in patients with acute myeloid leukemia in remission, Leukemia, vol.330, issue.3, pp.527-536, 2012. ,
DOI : 10.1038/leu.2011.215
gene, Leukemia & Lymphoma, vol.47, issue.4, pp.867-70 ,
DOI : 10.1038/onc.2010.444
-Mutated De Novo Acute Myeloid Leukemia: A Study by the Acute Leukemia French Association Group, Journal of Clinical Oncology, vol.32, issue.4, pp.297-305 ,
DOI : 10.1200/JCO.2013.50.2047
URL : https://hal.archives-ouvertes.fr/halshs-00159466
Clofarabine-based consolidation improves relapse-free survival of younger adults with non-favorable acute myeloid leukemia (AML) in first remission: results of the randomized ALFA-0702/CLARA study, Blood, vol.126, issue.23, 2015. ,
Protocols for determination of limits of detection and limits of quantitation: approved guideline, 2004. ,
Clinical characteristics of patients with de novo acute myeloid leukaemia and isolated trisomy 11: a Cancer and Leukemia Group B study, British Journal of Haematology, vol.305, issue.3, pp.513-533, 1998. ,
DOI : 10.1002/(SICI)1096-8652(199705)55:1<41::AID-AJH8>3.0.CO;2-3
Molecular alterations of isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) metabolic genes and additional genetic mutations in newly diagnosed acute myeloid leukemia patients, Journal of Hematology & Oncology, vol.5, issue.1, pp.5-230, 2012. ,
DOI : 10.1038/leu.2010.113
The MLL partial tandem duplication: evidence for recessive gain-of-function in acute myeloid leukemia identifies a novel patient subgroup for molecular-targeted therapy, Blood, vol.106, issue.1, pp.345-52, 2005. ,
DOI : 10.1182/blood-2005-01-0204